Published on : Feb 08, 2017
Albany, New York, February 8, 2017: The expanding database of Market Research Hub (MRH) has been recently updated by the addition of a new study which is titled as “Alzheimers Disease- Heat Map and Analysis”. This tabular heatmap context, intends to provide a summary of the clinical characteristics of the disease and also offers detailed information on all late-stage clinical trial outcomes for products in the AD market & its Phase III pipeline. Other than this, approval of novel therapies, clinical outcomes of leading marketed therapies, the positioning of new therapies are also discussed in the report. Following this, pipeline drugs for AD that diverge from well-established to first-in-class to novel molecules and their molecular targets are looked into in this report.
The main focus of this study is to provide a precise analysis of the clinical benchmarks set by the current market landscape along with further foreseen changes to these benchmarks, and to the treatment algorithm. Besides, marketed products and pipeline products are also highlighted in details.
At first, the report describes the Alzheimer disease along with the treatment therapies. Basically, Alzheimer’s disease is an irreversible, progressive brain disorder that slowly abolishes memory and thinking skills and in the end, the ability to carry out the simplest tasks. Also, it is the most common cause of dementia among older adults. The symptoms like lapses of memory, inability to process questions and instructions etc. typically begin to first appear in their mid-sixties. Currently, Alzheimer's disease is ranked as the sixth leading cause of death in the United States because it accounts for 60 to 80 percent of dementia cases.
Furthermore, it has been also analyzed that the symptoms can be treated with medication, however, there is no cure. The effects of AD, particularly at an advanced stage are distressing to patients and their caretakers. So, there is a worldwide effort under way to find better ways to treat the disease and prevent it from developing. According to the study, among several therapeutic options, only six symptomatic treatment healings have been agreed, of which one (Cognex) is no longer available in the United States. The current market leaders are suboptimal in terms of effectiveness, and there is a large unmet need within AD to improve safer and more efficient cures.
Click here to get more info with TOC in a PDF Format:http://www.marketresearchhub.com/enquiry.php?type=S&repid=915814
Moreover, it measures the safety and efficacy of treatment options that are currently given for AD, with an emphasis on product profiles of marketed therapies and a heat map representation of a comparison of the safety and efficacy of drugs. Through this report, the readers will be able to understand the current clinical landscape by considering the treatment options available by drug class.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-866-997-4948US Toll Free
Email : email@example.com